Mesoblast Limited
A maker of "off-the-shelf" cellular medicines, Mesoblast turns adult stem cells from bone marrow into treatments for severe inflammatory conditions, including its therapy Ryoncil for a life-threatening complication of bone-marrow transplants. Founded in Melbourne in 2004 by Dr. Silviu Itescu, its name blends "mesenchyme" (its cell type) with "-blast," a biological term for a developing cell. In late 2024 Ryoncil became the first stem-cell therapy of its kind to win US approval.
American Depositary Receipts
Bought 16.22M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| George GregoryDirector, 10% owner · 30 transactions | — | 246.27M | — | 16.22M | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +16.22M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.